2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Lung Neoplasms
10
Adenocarcinoma of Lung
7
Neoplasms
6
Neoplasm Metastasis
5
Melanoma
3
Glioblastoma
3
Carcinoma
3
cMET-dysregulated Advanced Solid Tumors
2
Sarcoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
cMET Dysegulation Advanced Solid Tumors
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Noonan Syndrome 6
1
Neuroblastoma
1
Malignant Non-small Cell Neoplasm of Lung Stage IV
1
Lymphoproliferative Disorders
1
Liver Neoplasms
1
Laryngeal Diseases
1
Kidney Neoplasms
1
Hepatic Impairment
1
Glioma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Interventions
Cyclophosphamide
101
Etoposide
60
Carboplatin
55
Vincristine
51
Filgrastim
49
Topotecan
44
Temozolomide
44
Melphalan
44
Isotretinoin
44
Doxorubicin
44
Irinotecan
42
Cisplatin
35
3-Iodobenzylguanidine
34
Peripheral Blood Stem Cell Transplantation
31
dinutuximab
30
Granulocyte Colony-Stimulating Factor
30
Radiotherapy
29
sargramostim
28
Granulocyte-Macrophage Colony-Stimulating Factor
25
Busulfan
22
Magnetic Resonance Spectroscopy
19
aldesleukin
18
Thiotepa
18
fludarabine
17
Interleukin-2
17
humanized 3F8 anti-GD2 monoclonal antibody
16
etoposide phosphate
16
naxitamab
15
Ifosfamide
15
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled